Login
Companies $IOVA
$7.50 -$0.05 (0.66%) After hours
IOVANCE BIOTHERAPEUTICS, INC. logo

IOVANCE BIOTHERAPEUTICS, INC.

iovance.com

What Do They Do?

Sells patient-specific immune-cell therapies for solid tumors and an interleukin medicine to hospitals, clinics and distributors.

How Do They Make Money?

Customers buy Amtagvi for treatment, with sales tied to patient infusion; Proleukin sales are tied to shipment or delivery.

revenue
SegmentShareRevenue
Amtagvi
Sold outright

84%
PROLEUKIN
Sold outright

17%

Who Are Their Customers?

Hospitals and clinics buy products, alongside U.S. distributors and wholesalers; Proleukin also goes through distributors abroad and to clinical, manufacturing and research customers.

Do Revenues Turn Into Profits?

No. It lost $391M in FY2025.

Operating income, FY2025
−153% of revenue
▼ −2% (Loss) vs FY2024 (−$395.3M, −241%)
Net income, FY2025
−148% of revenue
▼ −5% (Loss) vs FY2024 (−$372.2M, −227%)
Free cash flow, FY2025
−128% of revenue
▲ +8% (Loss) vs FY2024 (−$364M, −222%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +80%
vs $67.5M in Q3 FY2025
Net income
▲ +76% (Loss)
vs −$91.3M in Q3 FY2025
  • Jun 10, 2026 Australia approved Amtagvi for advanced melanoma The approval allows Iovance to pursue sales in Australia, where it is advancing authorization of its first treatment center.

From development to commercial sales The business moved from preparing to commercialize lifileucel to selling Amtagvi as an approved treatment, and added Proleukin after acquiring worldwide rights.

Revenue over time
Amtagvi PROLEUKIN
$500M$250M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support